Articles tagged with Metastasis
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Children in UK and Ireland diagnosed with larger kidney cancers, leading to late diagnosis and potential poorer outcomes. A call for frontline healthcare workers to be trained in paediatric medicine has been made to improve early detection.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A study published in Nature Communications found that neuroendocrine tumors in the small intestine often originate from different cells with unique genetic mutations. This breakthrough challenges conventional wisdom on cancer development and highlights the importance of removing all detected tumors to prevent late relapses.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
Researchers found that tumors with few micro-blood vessels are associated with defective perfusion, impacting the efficiency of systemic chemotherapy. This study highlights the importance of improving diagnostic imaging equipment to better detect lymph node metastasis and curb cancer-related mortality.
Researchers in mice found that chemotherapy enhances cancer's spread by making blood vessel walls more receptive, allowing cancer cells to latch on. The study shows how a chemo drug like cyclophosphamide alters non-cancer cells' properties, facilitating the cancer cells' attachment and progression.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Researchers found that aggressive triple-negative breast cancer cells use swiprosin-1 to hijack a cellular conveyor belt, increasing integrin circulation and cell migration. High swiprosin-1 expression correlates with metastasis formation and malignancy in breast cancer.
Researchers from UPV/EHU and Biocruces pathologists use game theory to study tumor cell interactions, finding that higher cell diversity may be beneficial for patients. This approach reveals the importance of collective stability in tumor cells' pursuit of better environments.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
New research reveals that boosting numbers of immune cells called dendritic cells may be key to overcoming colorectal cancers' immunotherapy resistance. By augmenting dendritic cells in liver metastases, treatment led to increased cytotoxic T lymphocytes and made tumors sensitive to immune checkpoint inhibitors.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
A new study reveals a small molecule, RGX-202, that targets and prevents metastasis in colorectal cancer by blocking the uptake of phosphocreatine into cancer cells. The findings have led to a clinical trial in humans and may eventually increase survival rates for multiple gastrointestinal cancers.
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Researchers from FAU and MIT develop a microfluidic assay to study the mechanical performance of red blood cells under hypoxic conditions. The study reveals that cyclic hypoxia can lead to mechanical degradation of the red blood cell membrane, contributing to aging.
Scientists discovered a protein, IL13Ra2, that promotes brain metastases in breast cancer patients. High levels of this protein are associated with poor survival rates. Researchers aim to develop targeted therapies for this specific population.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.
The KEYNOTE-826 study found that adding immunotherapy to standard first-line treatment increases overall survival by eight months for patients with recurrent, persistent or metastatic cervical cancer. The addition of pembrolizumab to chemotherapy also reduced the risk of death and disease progression by 33%.
A novel population of long-lived T cells, called 'lymph node resident memory T cells,' provides protection against melanoma by persisting in lymph nodes. These cells were found to counteract melanoma spreading in mice and predicted better outcomes for human melanoma patients with lymph node metastases.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...
The Vilcek Foundation has awarded four prizes worth $250,000 to foreign-born scientists in the United States. The prizes recognize outstanding career contributions to biomedical science and innovative research. This year's recipients include Vishva M. Dixit, Markita del Carpio Landry, Hani Goodarzi, and Harris Wang.
Research from Osaka City University reveals that hepatocellular carcinoma survival decreases as poorly differentiated tumor size increases. Tumors over 5cm have a significantly higher risk of early recurrence and spreading to other parts of the body.
Researchers identified a new growth factor produced by blood vessels that enables tumor cells to metastasize. The study, led by Hellmut Augustin, found that the production of LRG1 promotes the formation of a microenvironment that stimulates cancer cell growth and colonization.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
A study in HNSC patients found that specific microRNAs, such as hsa-miR-203a-3p, mir-10a-5p, and miR-194-5p, are strongly associated with lymphovascular invasion (LVI). These miRNAs regulate biological pathways involved in tumor progression, making them potential prognostic indicators.
Researchers at Duke University Medical Center identified a mechanism where breast cancer cells use cholesterol to develop tolerance to stress, allowing them to resist ferroptosis and proliferate. This finding highlights the importance of lowering cholesterol in preventing cancer progression and offers new approaches for treatment.
A recent study by Chinese Academy of Sciences researchers found that circular RNA circURI1 inhibits the spread of gastric cancer cells. It achieves this by sequestering hnRNPM, modulating alternative splicing in gastric cancer cells. This breakthrough provides a new perspective on the molecular basis of cancer metastasis.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
Researchers have found that breast cancer stem cells accumulate near a tumor arteriole, which they call the arteriolar niche. This niche promotes cancer cell features and potential development through the LPA/PKD-1 signaling pathway.
Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers at City of Hope found that advanced colorectal cancer patients with no liver metastases respond to checkpoint inhibitors, achieving a major response in 20% of cases. In contrast, patients with liver metastases showed no positive response to immunotherapy.
Prokineticin-1 is a lymphangiogenic factor involved in human colorectal cancer's lymph node metastasis and lymph vessel formation. High PROK1 expression was found to significantly increase the rate of lymph node metastasis.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Researchers found that cancer cells in lymph nodes avoid immune destruction due to increased physical forces causing impairment of T cell entry. Alleviating solid stress with losartan boosts blood vessels and T cells, suggesting a potential strategy to improve immune responses.
A study found that 50% of metastatic colorectal cancer patients treated with bevacizumab experienced RAS mutation disappearance, suggesting the drug's potential to revert tumors. This discovery may open new therapeutic avenues for primarily RAS mutant patients.
A preclinical study identifies a small molecule inhibitor, KCN1, that dampens tumor drivers and limits disease progression. The study showed KCN1 to be well-tolerated and effective at reducing metastasis, suggesting potential as a treatment for metastatic uveal melanoma.
A new study published in PNAS has identified a protein called AXL as a crucial player in hypoxia, which promotes cancer progression and resistance to treatment. By blocking the action of this protein, researchers observed improved recovery of blood vessels and revitalization of the tumour's immune environment.
Researchers found that reducing PTHrP levels can prevent metastasis and improve survival in mice with pancreatic cancer. The study also showed promising results with anti-PTHrP antibodies targeting human pancreatic cancer cells, offering a new potential treatment approach.
The German National Academy of Sciences Leopoldina hosted a virtual symposium to discuss cancer research, particularly pancreatic cancer, and palliative care. Experts shared insights into the development of rare pancreatic tumors, mechanisms leading to metastasis formation, and resilience in palliative care.
Researchers at University of Arizona Health Sciences found that cancer cells become more aggressive when exposed to tissue stiffening, leading to changes that persist over time. The 'mechanical conditioning' score can quantify these cellular changes and predict patients at high risk for bone metastasis.